Objective
to compare efficacy and safety between prasugrel and tricagrelor in patients with AMI undergoing PCI
Study
open-Label, multicentre, superiority randomized trial
Population
patients with AMI treated with Primary PCI
Endpoints
combined endpoint: cardiovascular death, MI or stroke at 1 year
Conclusion
Prasugrel and Tricagrelor are similarly effective during the first year after MI
Motovska et al. JACC. 2018;71:371-81